^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 negative + PGR positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    2064; 5241
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    11ms
    CDK and Body Composition Study (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Montefiore Medical Center | N=20 --> 30 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive • HER-2 negative + PGR positive
    11ms
    A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=550, Recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Kisqali (ribociclib)
    11ms
    DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Criterium, Inc. | N=100 --> 70 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER negative • PGR positive • ER positive + HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Signatera™ • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Ibrance (palbociclib) • fulvestrant
    11ms
    A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer (clinicaltrials.gov)
    P1/2, N=71, Completed, Joyce Marie Slingerland, MD | Phase classification: P2 --> P1/2
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + PGR positive
    |
    anastrozole • saracatinib (AZD0530)
    11ms
    CAR T Cells in Mesothelin-Expressing Breast Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSLN (Mesothelin)
    |
    ER positive • HER-2 negative • ER negative • MSLN expression • PGR positive • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    11ms
    Young-PALETTA: PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study (clinicaltrials.gov)
    P2, N=178, Recruiting, Samsung Medical Center | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2021 --> Dec 2025
    Enrollment open • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset)
    |
    BRCA2 mutation • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Tecentriq (atezolizumab) • Ibrance (palbociclib) • Talzenna (talazoparib)
    11ms
    COOL-IT: Cryoablation vs Lumpectomy in T1 Breast Cancers (clinicaltrials.gov)
    P=N/A, N=256, Recruiting, Washington University School of Medicine | Trial completion date: Oct 2031 --> Apr 2034 | Trial primary completion date: Oct 2031 --> Apr 2034
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER positive + PGR positive • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
    11ms
    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=169, Completed, Cyteir Therapeutics, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Dec 2024
    Trial completion • Trial completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
    |
    gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
    12ms
    Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial. (PubMed, J Natl Cancer Inst)
    Our study suggests differential tamoxifen benefit by menopausal status. Improved long-term endocrine therapy prediction in premenopausal patients is needed and could involve molecular markers because standard tumor characteristics cannot predict benefit beyond 10 years.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen
    12ms
    Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PI3K (Phosphoinositide 3-kinases)
    |
    ER positive • HER-2 negative • ER positive + PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Ibrance (palbociclib) • fulvestrant
    12ms
    RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Oana Danciu | Trial completion date: Dec 2027 --> Aug 2029 | Trial primary completion date: Dec 2024 --> Aug 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    12ms
    Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (clinicaltrials.gov)
    P1; Phase classification: P1/2 --> P1 | Trial completion date: Mar 2025 --> Jul 2025
    Combination therapy • Trial completion date • Phase classification • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
    |
    HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + PGR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)